HealthTronics clarifies shockwave study findings
This article was originally published in Clinica
Executive Summary
HealthTronics Surgical Services is seeking to defend the effectiveness of its shock wave orthopaedic therapy, after findings on the failings of a rival device were published in the Journal of the American Medical Association (September 18). HealthTronics, which saw its share price slump by around 40% on news of the article, said that it was "disappointed that the coverage of the study did not fully describe the issues".
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.